Genetic Screening
PGD (Preimplantation Genetic Diagnosis)
PGD (preimplantation genetic diagnosis) screens IVF embryos for specific genetic conditions or chromosomal abnormalities before transfer. This guide covers PGT-M versus PGT-A, the process and costs.
PGD vs PGT-A
PGD (PGT-M): Tests specific known genetic mutation - cystic fibrosis, sickle cell, Huntington's, muscular dystrophy, BRCA mutations. PGT-A (aneuploidy screening): Tests all chromosomes for number abnormalities - prevents Down syndrome, implantation failure, miscarriage.
Who Benefits
Genetic disease carriers, family history hereditary conditions, advanced maternal age (35+ - chromosome screening), recurrent miscarriage, recurrent IVF failure, chromosomal translocations, previous child with genetic condition.
Process
Day 5-6 blastocyst biopsy (5-10 cells from trophectoderm), genetic lab analysis 1-2 weeks, embryos frozen while awaiting results, unaffected embryos transferred in subsequent frozen cycle.
Success Impact
PGT-A increases pregnancy rates 10-15% per transfer (selects chromosomally normal embryos), reduces miscarriage risk 50-70%, shortens time to pregnancy. For single-gene disorders: Prevents affected pregnancy 95-99% accuracy.
PGD: Preventing Genetic Disease Transmission
Preimplantation Genetic Diagnosis (PGD), now termed PGT-M (Preimplantation Genetic Testing for Monogenic disorders), enables couples carrying serious genetic mutations to have biological children without transmitting disease. Embryo biopsy + genetic analysis identifies affected embryos before transfer. Only unaffected embryos transferred - 95-99% confidence preventing genetic disease.
PGD Testing Categories
1. PGT-M (Monogenic/single-gene disorders):
- Autosomal recessive (both parents carriers): Cystic fibrosis, sickle cell disease, Tay-Sachs, spinal muscular atrophy, thalassemia. 25% chance affected child each pregnancy naturally.
- Autosomal dominant (one parent affected): Huntington's disease, myotonic dystrophy, familial adenomatous polyposis, BRCA1/BRCA2 mutations (hereditary breast/ovarian cancer). 50% transmission chance naturally.
- X-linked (mother carrier): Duchenne/Becker muscular dystrophy, fragile X syndrome, hemophilia. Affects male offspring primarily.
2. PGT-A (Aneuploidy screening - chromosome number):
Screens all 23 chromosome pairs for correct number. Detects trisomies (Down syndrome, Edwards syndrome, Patau syndrome), monosomies (Turner syndrome), sex chromosome abnormalities. Main causes of implantation failure, miscarriage, intellectual disability.
Indications PGT-A: Advanced maternal age (35+ - 50% embryos abnormal age 40), recurrent miscarriage (2-3+ losses - chromosomal abnormalities cause 50-70%), recurrent implantation failure (3+ failed IVF transfers), male factor infertility (slightly increased chromosome error rates), desire to maximize single embryo transfer success (reduce multiple pregnancy risk while maintaining success rates).
3. PGT-SR (Structural rearrangements):
Tests for chromosomal translocations, inversions. One partner carries balanced translocation (chromosomes rearranged but all genetic material present - phenotypically normal). High miscarriage rates, affected offspring risk. PGT-SR identifies balanced/normal embryos vs unbalanced (missing/extra genetic material).
PGD Process: Technical Details
Pre-cycle preparation: Genetic counseling reviews inheritance patterns, risks, PGD limitations. Blood samples from couple (and affected family members if available) sent genetic lab. Lab develops probe targeting specific mutation. 4-8 weeks pre-cycle preparation typical before starting IVF.
IVF cycle: Standard ovarian stimulation, egg retrieval, ICSI fertilization (required - sperm washing ensures no contaminating DNA). Embryos cultured to Day 5-6 blastocyst stage (100-200 cells).
Biopsy procedure: Embryologist removes 5-10 cells from trophectoderm (future placenta) using laser-assisted hatching + aspiration. Cells sent genetics lab. Embryo immediately frozen (vitrification) while awaiting results. Biopsy doesn't harm embryo - trophectoderm regenerates, inner cell mass (future baby) untouched.
Genetic analysis (1-2 weeks): PCR amplification + sequencing/microarray analysis. Single-gene disorders: Directly tests specific mutation. Aneuploidy: Assesses all chromosomes via NGS (next-generation sequencing) or microarray. Results classify embryos: unaffected/normal, affected/abnormal, no result/inconclusive (rare).
Embryo transfer: Subsequent cycle (1-2 months after retrieval), uterine lining prepared with hormones. Unaffected embryos thawed, transferred. Standard frozen embryo transfer protocol.
PGD Accuracy & Limitations
Accuracy: 95-99% for single-gene disorders, 95-97% for aneuploidy screening. Rare errors due to mosaicism (embryo has both normal and abnormal cells - biopsy samples abnormal cells but embryo predominantly normal, or vice versa). Confirmatory prenatal testing (CVS at 11-13 weeks or amniocentesis 15-20 weeks) recommended even after normal PGD.
Limitations:
- Requires IVF: Even naturally fertile couples must undergo IVF for PGD access. Invasive, expensive.
- Not all embryos may be normal: Couples may produce multiple embryos but all test affected/abnormal. Difficult outcome requiring additional cycles.
- Doesn't test all diseases: Only tests specific mutations/chromosomes requested. Cannot screen for all possible genetic conditions.
- False positives/negatives: Rare (<1-3%) but possible. Mosaicism main cause.
- Embryo survival: Biopsy itself doesn't harm embryos (99%+ survive biopsy), but freeze-thaw cycle has 2-5% attrition.
Ethical Considerations
PGD raises complex ethical questions: Embryo selection (screening out affected embryos - some view as discrimination against disability), sex selection (medically indicated X-linked diseases vs non-medical gender preference - illegal many countries), "designer babies" concerns (PGD limited to disease prevention, not enhancement traits), unused affected embryo disposition (discard vs donate research).
Most ethical frameworks support PGD for serious genetic disease prevention (beneficence - preventing suffering outweighs embryo selection concerns). Non-medical sex selection, cosmetic trait selection generally prohibited.
Costs
| Testing Type | USA | International |
|---|---|---|
| PGT-M (Single Gene) | $5,000-$8,000 | $2,500-$4,000 |
| PGT-A (Aneuploidy) | $3,000-$5,000 | $1,500-$2,500 |
| Probe Development | +$1,000-$3,000 | +$500-$1,500 |
Per embryo pricing: Some clinics charge per embryo tested ($200-$400/embryo). Others flat fee regardless of embryo number.
FAQ
Will PGD harm my embryos?
No—biopsy technique safe. 99%+ embryos survive biopsy. Trophectoderm cells (future placenta) removed—inner cell mass (future baby) untouched. Decades of data show ICSI/PGD babies have normal development rates.
What if all embryos test abnormal?
Difficult outcome but occurs 10-20% of PGT-A cycles (higher >40 years). Options: Additional IVF cycle, donor eggs if age-related, accept diagnosis and pursue adoption/child-free living. Genetic counseling helps process results, plan next steps.
Is PGD 100% accurate?
95-99% accurate but not perfect. Mosaicism (embryo has both normal/abnormal cells) causes rare errors. Confirmatory prenatal testing (CVS/amniocentesis) recommended even after normal PGD—ensures accuracy. Most couples accept confirmation testing burden for disease prevention confidence.